FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988801996> ?p ?o ?g. }

• W1988801996 abstract "Introduction In February 2008, the European product label for darbepoetin alfa (DA) in the treatment of chemotherapy-induced anaemia (CIA) was changed to stipulate target haemoglobin (Hb) values between 10 and 12 g/dL. EORTC guidelines on ESA use state similar Hb target levels. The primary aim of this study is to assess adherence to the recommended Hb target range in patients (pts) receiving DA in routine clinical practice. Methods This prospective, multicenter, observational study evaluated the routine clinical practice use of DA in 11 European countries in pts with various non-myeloid malignancies (breast, colorectal, ovarian and lung cancer) at any time during chemotherapy treatment. Key outcome measures were Hb levels and the requirement for red blood cell (RBC) transfusions. Results 336 (mean±SD age 61.8±10.9 years) out of 1300 pts were included in this interim analysis. 80 pts had breast, 57 colorectal, 131 lung (33 small cell lung and 98 non-small cell lung cancer) and 68 ovarian cancer. 25% and 61% of pts had stage 3 and 4 disease at baseline, respectively. At baseline, 60% of all pts (53% of breast cancer and 62% of lung cancer pts) had a baseline Hb value of At week 9, Hb values for 243 pts (72%) were available. Of these, 136 pts (56%) had Hb levels between 10 and 12 g/dL, 59 pts (24%) had a Hb value > 12 g/dL and for 48 pts (20%), a Hb value below 10 g/dL was reported. The Kaplan-Meier percentage of pts with Hb levels ⩾10 g/dL was 89% (see table). The Kaplan-Meier percentage of pts requiring RBC transfusions from week 5 to end of treatment period was 17% (see table). A median DA dose of 500 μg was administered 3 times (median). Additional efficacy outcomes are presented in the table below. A treatment related non-serious adverse drug reaction (back pain) was reported for one patient only. Table 1Efficacy outcomes Total Breast cancer Lung cancer n (%) 336 (100) 80 (24) 131 (39) Hb (g/dL )at baseline, mean (SD) 9.8 (0.8) 9.9 (0.7) 9.7 (0.9) Hb (g/dL)at EOTP, mean (SD) 10.8 (1.6) 11.2 (1.4) 10.5 (1.7) K-M Hb⩾10 (g/dL) from wk 1 to EOTP, % (95% CI), na 89 (84, 95), 202 91 (82,101), 42 94 (85,102), 81 K-M RBC transfusions from wk 1 to EOTP, % (95% CI), n 26 (20, 31), 336 19 (8, 29), 80 37 (27, 46), 131 K-M RBC transfusions from wk 5 to EOTP, % (95% CI), nb 17 (12, 23), 208 12 (2, 22), 50 24 (14, 35), 72 CI, confidence interval; Hb, haemoglobin; EOTP, end of treatment period; K-M, Kaplan-Meier; RBC, red blood cell; wk, week.aOnly patients with Hb Conclusions This interim analysis suggests that the majority of pts were treated according to the European product label for DA and EORTC guidelines and did not surpass Hb levels of 12 g/dL. Furthermore, only 17% needed RBC transfusions from week 5 to end of treatment period. These data further support the effectiveness of DA for the treatment of pts with CIA. Sponsored by Amgen GmbH." @default.
• W1988801996 created "2016-06-24" @default.
• W1988801996 creator A5006924763 @default.
• W1988801996 creator A5014722961 @default.
• W1988801996 creator A5017559108 @default.
• W1988801996 creator A5069041063 @default.
• W1988801996 creator A5071719493 @default.
• W1988801996 creator A5085012338 @default.
• W1988801996 creator A5088070101 @default.
• W1988801996 date "2009-12-01" @default.
• W1988801996 modified "2023-10-01" @default.
• W1988801996 title "CHOICE, an international, observational study to examine current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemia" @default.
• W1988801996 doi "https://doi.org/10.1016/j.eujim.2009.08.006" @default.
• W1988801996 hasPublicationYear "2009" @default.
• W1988801996 type Work @default.
• W1988801996 sameAs 1988801996 @default.
• W1988801996 citedByCount "3" @default.
• W1988801996 crossrefType "journal-article" @default.
• W1988801996 hasAuthorship W1988801996A5006924763 @default.
• W1988801996 hasAuthorship W1988801996A5014722961 @default.
• W1988801996 hasAuthorship W1988801996A5017559108 @default.
• W1988801996 hasAuthorship W1988801996A5069041063 @default.
• W1988801996 hasAuthorship W1988801996A5071719493 @default.
• W1988801996 hasAuthorship W1988801996A5085012338 @default.
• W1988801996 hasAuthorship W1988801996A5088070101 @default.
• W1988801996 hasConcept C121608353 @default.
• W1988801996 hasConcept C126322002 @default.
• W1988801996 hasConcept C143998085 @default.
• W1988801996 hasConcept C146357865 @default.
• W1988801996 hasConcept C151730666 @default.
• W1988801996 hasConcept C23131810 @default.
• W1988801996 hasConcept C2776256026 @default.
• W1988801996 hasConcept C2776694085 @default.
• W1988801996 hasConcept C2780427987 @default.
• W1988801996 hasConcept C2781404941 @default.
• W1988801996 hasConcept C526805850 @default.
• W1988801996 hasConcept C530470458 @default.
• W1988801996 hasConcept C535046627 @default.
• W1988801996 hasConcept C61943457 @default.
• W1988801996 hasConcept C71924100 @default.
• W1988801996 hasConcept C86803240 @default.
• W1988801996 hasConcept C90924648 @default.
• W1988801996 hasConceptScore W1988801996C121608353 @default.
• W1988801996 hasConceptScore W1988801996C126322002 @default.
• W1988801996 hasConceptScore W1988801996C143998085 @default.
• W1988801996 hasConceptScore W1988801996C146357865 @default.
• W1988801996 hasConceptScore W1988801996C151730666 @default.
• W1988801996 hasConceptScore W1988801996C23131810 @default.
• W1988801996 hasConceptScore W1988801996C2776256026 @default.
• W1988801996 hasConceptScore W1988801996C2776694085 @default.
• W1988801996 hasConceptScore W1988801996C2780427987 @default.
• W1988801996 hasConceptScore W1988801996C2781404941 @default.
• W1988801996 hasConceptScore W1988801996C526805850 @default.
• W1988801996 hasConceptScore W1988801996C530470458 @default.
• W1988801996 hasConceptScore W1988801996C535046627 @default.
• W1988801996 hasConceptScore W1988801996C61943457 @default.
• W1988801996 hasConceptScore W1988801996C71924100 @default.
• W1988801996 hasConceptScore W1988801996C86803240 @default.
• W1988801996 hasConceptScore W1988801996C90924648 @default.
• W1988801996 hasLocation W19888019961 @default.
• W1988801996 hasOpenAccess W1988801996 @default.
• W1988801996 hasPrimaryLocation W19888019961 @default.
• W1988801996 hasRelatedWork W1976186161 @default.
• W1988801996 hasRelatedWork W2189203119 @default.
• W1988801996 hasRelatedWork W2262338412 @default.
• W1988801996 hasRelatedWork W2315057995 @default.
• W1988801996 hasRelatedWork W2522654573 @default.
• W1988801996 hasRelatedWork W2549614462 @default.
• W1988801996 hasRelatedWork W2551278569 @default.
• W1988801996 hasRelatedWork W2551697620 @default.
• W1988801996 hasRelatedWork W2552274424 @default.
• W1988801996 hasRelatedWork W2555391291 @default.
• W1988801996 hasRelatedWork W2557489153 @default.
• W1988801996 hasRelatedWork W2557927528 @default.
• W1988801996 hasRelatedWork W2560371591 @default.
• W1988801996 hasRelatedWork W2563571469 @default.
• W1988801996 hasRelatedWork W2572782996 @default.
• W1988801996 hasRelatedWork W2582787413 @default.
• W1988801996 hasRelatedWork W2811428019 @default.
• W1988801996 hasRelatedWork W2998985124 @default.
• W1988801996 hasRelatedWork W2999862035 @default.
• W1988801996 hasRelatedWork W3047389906 @default.
• W1988801996 isParatext "false" @default.
• W1988801996 isRetracted "false" @default.
• W1988801996 magId "1988801996" @default.
• W1988801996 workType "article" @default.